How to Prepare Performance Verification Documentation for Medical Device Registration in Saudi Arabia

Direct answer: Performance verification documentation for Saudi SFDA medical device registration should not be assembled as a checklist exercise. It should be built from the product's intended use, mechanism of action, risk classification and applicable registration pathway, and it must stand up as part of a single consistent evidence chain. Before any document is drafted or translated, manufacturers should confirm the SFDA classification and pathway, the local authorized representative arrangement, and the actual gaps between the documentation they already hold (NMPA, CE, FDA, ISO 13485 and other market records) and what SFDA requires. Only then should they decide which items require additional testing, translation, notarization, or localization. Taking this sequence first is the most reliable way to reduce deficiency letters and to avoid reworking documents that could have been reused.

Published: 11 July 2026, 13:18 · Updated: 11 July 2026, 13:18

Applicable Scenarios and Core Questions

Companies searching for guidance on preparing performance verification documentation for Saudi registration are usually not looking for a conceptual explanation. They want to know whether their existing documentation can support a submission in the target market, whether a local agent or authorized representative is required, why timelines get extended, and which issues could affect their launch plan. Behind this question there are normally several connected topics: product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or markets across Southeast Asia, the Middle East and Latin America at the same time, answering for one country in isolation is not sufficient. A more valuable approach is to first build reusable versions of the core technical file, quality system evidence, performance verification data, clinical evidence and labels/IFUs, and then localize them according to each national regulator's requirements.

Registration Decision Logic

Before Saudi registration, the intended use, mechanism of action, risk level, existing foreign registrations, and whether the device involves sterility, software, IVD, implantable, home monitoring or electrical safety requirements should all be confirmed. Documentation depth differs by product. The requirements for clinical evidence, performance verification and post-market surveillance data for a low-risk device cannot be treated in the same way as those for a high-risk device.

For Chinese manufacturers, the more reliable approach is to conduct a gap assessment first using existing Chinese and English materials, and then decide which documents need translation, restructuring, additional testing, or supplementary declarations. This reduces repeated deficiency responses and avoids redoing documentation that could have been reused.

Documentation and Evidence

Saudi SFDA medical device registration generally requires coverage of the following documentation:

• Manufacturer corporate information
• Product name, models and specifications
• Intended use and product description
• Basis for risk classification
• Technical file
• ISO 13485 quality management system certificate
• Performance verification or test reports
• Risk management documentation
• Clinical evaluation or clinical evidence
• Labels and instructions for use
• Declaration of conformity
• Authorized representative documentation
• Evidence of prior marketing authorization or registration certificates from other countries

The area most prone to problems is evidence-chain consistency. The indications in the IFU, the functional claims in promotional materials, the models covered by test reports, the equivalent device used in the clinical evaluation, and the hazard analysis in the risk management file should all correspond to one another. What a regulator actually reviews is not whether documents exist, but whether these documents together demonstrate that the device is safe, effective and traceable for its intended use.

Common Mistakes

The most common problem is treating registration as a simple document submission exercise without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting translated NMPA documentation directly, without re-sequencing the evidence according to the target market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local agent purely on commercial sales grounds, without defining regulatory responsibilities, certificate control, and post-market maintenance obligations.
• Inconsistency between claims in labels, IFUs, promotional materials and registration documents, resulting in deficiency letters or post-market compliance risk.
• Failing to plan for multi-country document reuse in advance, so that materials are rebuilt country by country and both cost and timelines expand.

Pre-Submission Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation baseline, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English IFU.
• Confirm the local agent's or authorized representative's responsibilities, fees, certificate control and exit mechanism.
• Build a target-country gap assessment table identifying what needs additional testing, translation, notarization or supplementary declarations.

AIMEILI's Perspective

AIMEILI recommends that companies treat target-market registration not as a one-off document submission, but as an overseas market access program to be managed. For companies entering multiple countries, establishing a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster, more stable, and better for later changes and renewals than filling documentation gaps on an ad hoc country-by-country basis.

From a project management standpoint, three items should be controlled early: first, product classification and pathway determination; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, the project can still run into repeated deficiency responses, agent communication problems and post-market maintenance issues, no matter how voluminous the documentation appears.

Frequently Asked Follow-Up Questions

Can NMPA documentation be used directly for Saudi registration?

It can serve as source documentation, but it cannot directly replace the Saudi submission file. Companies still need to perform classification determination and document restructuring in line with SFDA requirements, prepare English-language or locally required documents, and adapt labels and IFUs accordingly.

Is a local authorized representative mandatory for Saudi registration?

Foreign manufacturers typically require a locally compliant entity to support registration communication and post-market maintenance. The scope of authorization, certificate control and the mechanism for subsequent changes should be defined before cooperation begins.

Can incomplete documentation be submitted first?

Submission is not advisable when critical documents are missing. The absence of a classification basis, performance verification, clinical evidence or label documents will extend the deficiency response cycle and may also affect the determination of the registration pathway.

Quality System and Evidence Consistency

From a review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the device being registered, or if the manufacturing address, model specifications or IFU version are inconsistent with the test reports, additional clarification may be requested even when a large volume of documentation has been prepared.

Companies should build an evidence consistency checklist before submission, mapping each item across product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version, and quality system certificate. This step appears basic, but it noticeably lowers the probability of deficiency letters, particularly for projects registering across multiple GHWP member states or for several product families at the same time.

Localization and Authorized Representative Responsibilities

Target-market registration projects usually involve arrangements with a local agent, authorized representative, importer or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents, or also handles regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and the stability of the market presence going forward.

Labels, IFUs and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is converting reusable evidence into a submission structure acceptable to the target country, rather than writing a separate, isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration approval does not mean the compliance work is finished. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall processes, label versions and regulatory update records. Many companies invest heavily in obtaining a certificate but neglect post-market maintenance, and later find that a change of manufacturing site, model extension, IFU update or change of agent leaves the certificate out of step with actual market sales.

AIMEILI recommends managing this topic within an annual international registration plan: define target-market priorities first, then build a reusable documentation package and country gap lists, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach is not only greater registration efficiency in a single country; more importantly, it helps a company build a repeatable overseas compliance capability and reduces the cost of starting from scratch every time it enters a new market.

Related Reading

• What are the risk management documentation requirements for medical device registration in Saudi Arabia?
• How should inconsistencies in quality system evidence be handled for Saudi medical device registration?
• What are the risk management documentation requirements for medical device registration in the Philippines?
• How to prepare performance verification documentation for medical device registration in the Philippines
• How should inconsistencies in quality system evidence be handled for medical device registration in the Philippines?
• How to prepare registration documentation for medical device registration in Singapore
• How to determine product classification for medical device registration in Singapore
• How to organize the technical file for medical device registration in Singapore

Sources, Review and Scope of Application

Compiled from: AIMEILI regulatory practice question bank, the international medical device registration knowledge base, and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country's regulator and on the actual product documentation baseline.

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI International Medical Device Registration Project Team.

Source principles: Priority is given to official regulatory authorities, international organizations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal advice.